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Supplementary material – CSF assay methodology
Total tau (T-tau), phosphorylated tau (P-tau) and β-amyloid 1-42 (Aβ1-42) were
analyzed using INNOTEST enzyme-linked immunosorbent assays (ELISAs (Fujirebio
Europe N.V., Gent, Belgium). Other markers of amyloid processing were measured
using the MSD Aβ Triplex assay (Meso Scale Discovery, Rockville, MD), a multiplexed
method in which C-terminally specific antibodies are used selectively to capture Aβ
forms ending at amino acids 38, 40 and 42, respectively, which are then quantified
using the 6E10 detector antibody. This assay is thus not specific to the 1st amino acid of
the Aβ peptides (the epitope of 6E10 lies within amino acids 3 to 8 in the Aβ sequence)
and the measured Aβ isoforms are therefore called AβX-38, AβX-40 and AβX-42.
Neurofilament light chain (NFL) concentrations were determined using the NF-light
method (UmanDiagnostics, Umeå Sweden); YKL-40, also known as chitinase-3-like
protein 1 (CHI3L1), was measured using the Human Chitinase 3-like 1 Quantikine
ELISA Kit (R&D systems, Minneapolis, MN). Amyloid precursor protein soluble
metabolites α and β (sAPPα, sAPPβ) were measured using a commercial duplex
immunoassay with electrochemiluminescence detection (Meso Scale Discovery,
Rockville, MD). Inter-plate co-efficients of variation for internal standards (pooled AD
CSF) were: YKL-40: 9.59 %; NFL: 7.72%; sAPPα: 23.03%; sAPPβ: 28.56%; AβX-38:
5.52%; AβX-40: 7.57%; AβX-42: 10.17%.
Supplementary Table S1 Diagnostic accuracy of Aβ1-42, T-tau, T-tau/Aβ1-42 ratio, P-
tau and AβX-42/X-40 ratio in test and validation cohorts based on pre-LP diagnostic
classification and diagnostic accuracy in the pathologically or genetically defined sub-cohort.
AD: Alzheimer’s disease; DLB: dementia with Lewy bodies; bvFTD: behavioural variant
frontotemporal dementia; PNFA: progressive non-fluent aphasia; SD: Semantic dementia;
HC: healthy control.
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